Stereotactic Body-Radiotherapy Boost Dose of 18 Gy vs 21 Gy in Combination With Androgen-Deprivation Therapy and Whole-Pelvic Radiotherapy for Intermediate- Or High-Risk Prostate Cancer: A Study Protocol for a Randomized Controlled, Pilot Trial

Trials - United Kingdom
doi 10.1186/s13063-018-2574-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Benefit of Whole Pelvic Radiotherapy Combined With Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer

Journal of Biomedicine and Biotechnology
2009English

Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- And High-Risk Prostate Cancer Across the United States

JAMA Oncology
Cancer ResearchOncology
2016English

Optimal Neoadjuvant Radiotherapy Dose for Esophageal Cancer: An NCDB Analysis of 41.4 Gy Versus 50.4 Gy

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Combined Brachytherapy and External Beam Radiotherapy Without Adjuvant Androgen Deprivation Therapy for High-Risk Prostate Cancer

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2014English

High-Dose Radiation Employing External Beam Radiotherapy and High-Dose Rate Brachytherapy With and Without Neoadjuvant Androgen Deprivation for Prostate Cancer Patients With Intermediate- And High-Risk Features

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2006English

Three-Month Posttreatment Prostate-Specific Antigen Level as a Biomarker of Treatment Response in Patients With Intermediate-Risk or High-Risk Prostate Cancer Treated With Androgen Deprivation Therapy and Radiotherapy

Cancer
Cancer ResearchOncology
2018English

Evaluation of the Effectiveness of Adding Androgen Deprivation to Modern Dose-Escalated Radiotherapy for Men With Favorable Intermediate-Risk Prostate Cancer

Cancer
Cancer ResearchOncology
2016English

Individualized Higher Dose of 70–75 Gy Using Five-Fraction Robotic Stereotactic Radiotherapy for Non-Small-Cell Lung Cancer: A Feasibility Study

Computer Aided Surgery
2011English

A Phase I Dose-Escalation Trial of Stereotactic Body Radiotherapy Using 4 Fractions for Patients With Localized Prostate Cancer

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy